TIDMNSCI
NetScientific PLC
23 October 2023
Reach: For immediate release
NetScientific plc
Biotech Announces Preliminary Biomarker Study Results in Subset
of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO
Combination of PDS0101 and KEYTRUDA(R) appears to lead to
changes towards a TH1 predominant cytokine profile reported to be
associated with improved killer T cell activity
Lowered CD8 T cells in peripheral blood after treatment align
with previously reported CD8 T cell targeting and accumulation in
tumors(1)
NetScientific Plc (AIM: NSCI), the deep tech and life sciences
VC investment group, reports that its portfolio company, PDS
Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or "the
Company"), a clinical-stage immunotherapy company developing a
growing pipeline of targeted cancer immunotherapies and infectious
disease vaccines based on the Company's proprietary T cell
activating platforms, announced immune response data from a
preliminary analysis of a subset of patients in VERSATILE-002, the
Phase 2 clinical trial evaluating the safety and efficacy of
PDS0101 in combination with Merck's anti-PD-1 therapy KEYTRUDA(R)
(pembrolizumab) in patients with human papillomavirus
(HPV)16-positive recurrent or metastatic head and neck squamous
cell carcinoma (HNSCC). The data presented during the European
Society for Medical Oncology Congress 2023 (ESMO Congress 2023)
provided preliminary insight to the pre-existing immune responses
in advanced HPV-positive HNSCC patients and potential changes to
the immune profile after treatment.
Kevin Harrington, PhD, Professor of Biological Cancer Therapies,
The Royal Marsden
" Generation of multifunctional, anti-tumour T cells with the
relevant cytokine and chemokine profiles are necessary for
effective long-term control of tumour growth and clinical outcomes.
This initial study focused on understanding the immunological
profile of advanced head and cancer patients in the blood. This
preliminary study suggests that PDS0101 may promote a TH1
predominant cytokine profile as well as induction of important T
cell activating chemokines. Such studies could be helpful in
providing further insight into how PDS0101 in combination with
KEYTRUDA(R) alters T cell cytokine and chemokine profiles to
promote improved clinical outcomes."
The data presented at ESMO 2023 included 18 patients with a
median age of 63 years (range 46-83) and all had confirmed
HPV16-positive tumours. The immunological profiles were assessed at
three timepoints: pre-treatment,12 (cycle 5), and 36 weeks (cycle
13) following four and five cycles of combination therapy,
respectively.
Highlights of the analysis include:
-- Combination of PDS0101 and KEYTRUDA(R) appears to lead to
changes towards a TH1 predominant cytokine profile reported to be
associated with improved killer T cell activity
-- Combination of PDS0101 and KEYTRUDA(R) resulted in increased
polyfunctionality reflected in T cells expressing 5 or more
cytokines. Increased polyfunctionality is typically associated with
enhanced killing function and anti-tumour activity
Lauren V. Wood, MD, Chief Medical Officer of PDS Biotech
said:
"This analysis provides preliminary insights into how PDS0101 in
combination with KEYTRUDA(R) may be impacting specific cytokines
and chemokines in CD8 and CD4 T cell populations. The
investigational combination appears to be promoting a predominant
TH1 immunologic profile that is associated with decreases in CD8 T
cells in peripheral blood. We are encouraged that these
observations align with other Phase 2 studies reporting
PDS0101-induced polyfunctional CD8 T cells traffic to tumours and
we look forward to continued investigation in our VERSATILE-003
Phase 3 study."
1 Klopp A, et al. 2022. IMMUNOCERV, an ongoing Phase II trial
combining PDS0101, an HPV-specific T cell immunotherapy, with
chemotherapy and radiation for treatment of locally advanced
cervical cancers. Presented at: Society for Immunotherapy of
Cancer; November 8-12, 2022. Boston, MA. Abstract: 674.
A full version of PDS Biotech's announcement can be accessed
here:
PDS Biotech - PDS Biotech Announces Preliminary Biomarker Study
Results in Subset of Advanced HPV-Positive Head and Neck Cancer
Patients at ESMO
-Ends-
For more information, please contact:
NetScientific
Ilian Iliev, CEO Via Belvedere Communications
WH Ireland (NOMAD, Financial Adviser and Broker)
Chris Fielding / Darshan Patel +44 (0)20 7220 1666
Belvedere Communications
John West / Llew Angus +44 (0) 203 008 6867
Email: nsci@belvederepr.com
About NetScientific
NetScientific plc (AIM: NSCI) is a deep tech and life sciences
VC investment group with an international portfolio of innovative
companies.
NetScientific identifies, invests in, and builds high growth
companies in the UK and internationally. The company adds value
through the proactive management of its portfolio, progressing to
key value inflection points, and delivering investment returns
through partial or full liquidity events.
NetScientific differentiates itself by employing a capital-light
investment approach, making judicial use of its balance sheet and
syndicating investments through its wholly owned VC subsidiary, EMV
Capital. The group secures a mixture of direct equity stakes and
carried interest stakes in its portfolio of companies, creating a
lean structure that can support a large portfolio.
NetScientific is headquartered in London, United Kingdom, and is
admitted to trading on AIM, a market operated by the London Stock
Exchange.
www.netscientific.net
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing
a growing pipeline of targeted cancer and infectious disease
immunotherapies based on our proprietary Versamune(R) ,
Versamune(R) plus PDS0301, and Infectimune(R) T cell-activating
platforms. We believe our targeted immunotherapies have the
potential to overcome the limitations of current immunotherapy
approaches through the activation of the right type, quantity and
potency of T cells. To date, our lead Versamune(R) clinical
candidate, PDS0101, has demonstrated the ability to reduce and
shrink tumours and stabilize disease in combination with approved
and investigational therapeutics in patients with a broad range of
HPV16-associated cancers in multiple Phase 2 clinical trials and
will be advancing into a Phase 3 clinical trial in combination with
KEYTRUDA(R) for the treatment of recurrent/metastatic
HPV16-positive head and neck cancer in 2023. Our Infectimune(R)
based vaccines have also demonstrated the potential to induce not
only robust and durable neutralizing antibody responses, but also
powerful T cell responses, including long-lasting memory T cell
responses in pre-clinical studies to date. To learn more, please
visit www.pdsbiotech.com or follow us on Twitter at
@PDSBiotech.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABRBDGBDDDGXX
(END) Dow Jones Newswires
October 23, 2023 13:22 ET (17:22 GMT)
Netscientific (LSE:NSCI)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Netscientific (LSE:NSCI)
Gráfica de Acción Histórica
De May 2023 a May 2024